ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...
During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.
Dr Richard Goldberg discusses how outdated FDA metrics may delay immunotherapy approvals for oncology agents. Immunotherapy ...
Among 5-year survivors in the tebentafusp arm, 44% received tebentafusp as their only therapy. In contrast, 86% of control ...
Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results